MCID: AMP007
MIFTS: 36

Amphetamine Abuse

Categories: Mental diseases

Aliases & Classifications for Amphetamine Abuse

MalaCards integrated aliases for Amphetamine Abuse:

Name: Amphetamine Abuse 12 52 14

Classifications:



External Ids:

Disease Ontology 12 DOID:670
ICD9CM 35 305.7
UMLS 69 C0154536

Summaries for Amphetamine Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of amphetamines despite negative consequences.

MalaCards based summary : Amphetamine Abuse is related to intracranial cavernous angioma and conjunctival pigmentation. An important gene associated with Amphetamine Abuse is SLC6A3 (Solute Carrier Family 6 Member 3), and among its related pathways/superpathways are Circadian entrainment and Taste transduction. The drugs Amphetamine and Cocaine have been mentioned in the context of this disorder. Affiliated tissues include testes and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Amphetamine Abuse

Graphical network of the top 20 diseases related to Amphetamine Abuse:



Diseases related to Amphetamine Abuse

Symptoms & Phenotypes for Amphetamine Abuse

MGI Mouse Phenotypes related to Amphetamine Abuse:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 GRM2 GRM5 HTR1B HTR7 MAOB MAPK14
2 homeostasis/metabolism MP:0005376 9.7 NTS PRKCB PTGES SLC6A2 SLC6A3 GRM2
3 nervous system MP:0003631 9.36 ARC GRM2 GRM5 HTR7 MAOB MAPK14

Drugs & Therapeutics for Amphetamine Abuse

Drugs for Amphetamine Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphetamine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 300-62-9 5826 3007
2
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-36-2 5760 446220
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
5
Guaifenesin Approved, Vet_approved Phase 4,Phase 1 93-14-1 3516
6
Methamphetamine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 537-46-2 10836
7
Risperidone Approved, Investigational Phase 4,Phase 2 106266-06-2 5073
8
Acetaminophen Approved Phase 4 103-90-2 1983
9
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
10
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11
Phenobarbital Approved Phase 4 50-06-6 4763
12
Dextroamphetamine Approved, Illicit Phase 4,Phase 2,Phase 1,Early Phase 1 51-64-9 5826
13
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
14 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
16 Anesthetics, Local Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
17 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
20 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
27 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Vasoconstrictor Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
29 Analgesics Phase 4,Phase 1
30 Analgesics, Opioid Phase 4,Phase 1
31 Antitussive Agents Phase 4,Phase 1
32 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 1
33 Narcotics Phase 4,Phase 3,Phase 2,Phase 1
34 Respiratory System Agents Phase 4,Phase 1
35 Dopamine Antagonists Phase 4,Phase 2
36 Quetiapine Fumarate Phase 4 111974-72-2
37
Serotonin Phase 4,Phase 2,Phase 1 50-67-9 5202
38 Serotonin Agents Phase 4,Phase 2,Phase 1
39 Serotonin Antagonists Phase 4,Phase 2
40 Acetaminophen, hydrocodone drug combination Phase 4
41 Analgesics, Non-Narcotic Phase 4
42 Antipyretics Phase 4
43 adderall Phase 4,Phase 2,Phase 3
44 Lisdexamfetamine Dimesylate Phase 4,Phase 2,Phase 1
45
Aripiprazole Approved, Investigational Phase 3,Phase 1 129722-12-9 60795
46
Naltrexone Approved, Investigational, Vet_approved Phase 3,Phase 2 16590-41-3 5360515
47 Narcotic Antagonists Phase 3,Phase 2,Phase 1
48 Anti-Infective Agents Phase 3,Phase 2
49 Anti-Infective Agents, Local Phase 3
50
Armodafinil Approved, Investigational Phase 2,Phase 1 112111-43-0

Interventional clinical trials:

(show top 50) (show all 73)

id Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse - 11 Unknown status NCT00000346 Phase 4
2 Cognitive Correlates of Substance Abuse, Part 2 - 16 Unknown status NCT00000351 Phase 4
3 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
4 A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine Completed NCT00314340 Phase 4 ER Morphine;hydrocodone plus acetaminophen;placebo
5 Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder Recruiting NCT02566824 Phase 4 Methylphenidate or amphetamine product
6 The Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine Withdrawn NCT01529892 Phase 4 A single oral 5 mg of duterium labeled methamphetamine
7 Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland Completed NCT01100853 Phase 3 VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
8 Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence Completed NCT00553319 Phase 2, Phase 3 Placebo;Adderall-XR;Adderall-XR
9 Stimulant Abuser Groups to Engage in 12-Step Completed NCT00573183 Phase 3
10 Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder Recruiting NCT02803229 Phase 2, Phase 3 Adderall-XR;Matched placebo
11 Aripiprazole for Bipolar Disorder and Alcohol Use Disorder Recruiting NCT02918370 Phase 3 Aripiprazole;Placebo
12 A Dose Ranging Study of Modafinil for Methamphetamine Dependence Unknown status NCT00630097 Phase 2 modafinil
13 Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Completed NCT00247572 Phase 2 NRP104
14 Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2 NRP104
15 Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo Completed NCT00218348 Phase 2 Dextro-Amphetamine Sulfate
16 Caffeine and Cocaine Completed NCT00733993 Phase 1, Phase 2 Caffeine 150 MG;Placebo;Amphetamine;Caffeine 300 MG
17 Ondansetron for the Treatment of Methamphetamine Dependence - 1 Completed NCT00040053 Phase 2 Ondansetron
18 A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence Completed NCT00421603 Phase 2 Adderall-XR and Topiramate;Placebo
19 Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men Completed NCT01140880 Phase 2 Truvada
20 Dextroamphetamine-Cocaine Behavioral Intervention - 5 Completed NCT00000308 Phase 2 Dextroamphetamine;D-amphetamine;placebo
21 Bupropion for the Treatment of Methamphetamine Dependence - 1 Completed NCT00069251 Phase 2 Bupropion
22 Tyrosine for Methamphetamine Dependence - 1 Completed NCT00000322 Phase 2
23 Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM) Completed NCT01449565 Phase 2 Naltrexone;Placebo
24 PET Imaging of Dopamine in Healthy Study Participants Completed NCT00062946 Phase 2 (18F)fallypride
25 Dextroamphetamine as an Adjunct in Cocaine Treatment - 1 Completed NCT00000304 Phase 2 Dextroamphetamine;D-Amphetamine;Placebo
26 A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence Completed NCT00284206 Phase 2 long-acting injectable risperidone
27 Intermittent Naltrexone Among Polysubstance Users Completed NCT01723384 Phase 2 Intermittent Oral Naltrexone;Placebo
28 Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals Completed NCT00218062 Phase 2 D-Amphetamine 30mg;D-Amphetamine 60mg;Modafinil 200mg;Modafinil 400mg;Placebo
29 Study of Medical Treatment for Methamphetamine Addiction Completed NCT00833443 Phase 2 Bupropion
30 A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence Completed NCT00538655 Phase 2 modafinil
31 Risperidone for Treatment of Cocaine Dependence in Outpatients - 12 Completed NCT00000347 Phase 2 Risperidone
32 Atomoxetine Effects in Humans Completed NCT00607568 Phase 1, Phase 2 Atomoxetine
33 Trial Of NS2359 For The Treatment of Cocaine Dependence Recruiting NCT02798627 Phase 2 NS2359;placebo
34 Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0) Active, not recruiting NCT01888835 Phase 2 Mirtazapine;Placebo
35 Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1 Unknown status NCT00040040 Phase 1 Bupropion
36 Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1 Unknown status NCT00033072 Phase 1 Selegiline
37 Assessment of Interactions Between Methamphetamine and Aripiprazole - 1 Unknown status NCT00089440 Phase 1 Aripiprazole
38 Effects of Stimulant Dependence on Human Striatal Dopamine System - 15 Unknown status NCT00000350 Phase 1
39 A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1 Unknown status NCT00267657 Phase 1 Reserpine
40 Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1 Unknown status NCT00265278 Phase 1 Modafinil
41 To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1 Unknown status NCT00100074 Phase 1 Lobeline
42 Sustained Release d-Amphetamine & Buprenorphine on Drug Seeking Behavior in Opioid & Cocaine Dependent Individuals Completed NCT00429767 Phase 1
43 Abuse Liability and Human Pharmacology of Mephedrone Completed NCT02232789 Phase 1 Mephedrone;3,4-methylenedioxymethamphetamine;Placebo
44 A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users Completed NCT02144415 Phase 1 EB-1020 400 mg;EB-1020 800 mg;lisdexamfetamine 150 mg;d-amphetamine 40 mg;Placebo
45 Factors Affecting Methamphetamine and Opiates Drug Testing Completed NCT01736332 Phase 1 Vicks VapoInhaler
46 An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers Completed NCT00713479 Phase 1 Varenicline, then placebo;Placebo, then varenicline
47 Agonist Replacement Therapy for Cocaine Dependence Completed NCT00697138 Phase 1 d-Amphetamine; Atomoxetine
48 Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients Completed NCT00780702 Phase 1 Airipiprazole;Placebo
49 A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users Completed NCT00975481 Phase 1 dimebon;dimebon;dimebon;placebo;alprazolam;alprazolam
50 A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users Recruiting NCT03200080 Phase 1 Tozadenant;Placebo oral tablet;d-amphetamine;Placebo oral capsule

Search NIH Clinical Center for Amphetamine Abuse

Genetic Tests for Amphetamine Abuse

Anatomical Context for Amphetamine Abuse

MalaCards organs/tissues related to Amphetamine Abuse:

39
Testes, Brain

Publications for Amphetamine Abuse

Articles related to Amphetamine Abuse:

(show top 50) (show all 80)
id Title Authors Year
1
Cardiovascular Complications of Acute Amphetamine Abuse: Cross-sectional study. ( 28417026 )
2017
2
Facial movement disorder and dopamine imaging in a patient with amphetamine abuse. ( 27502592 )
2016
3
Tamoxifen and amphetamine abuse: Are there therapeutic possibilities? ( 27585851 )
2016
4
Amphetamine Abuse Related Acute Myocardial Infarction. ( 26998366 )
2016
5
Amphetamine abuse as a rare cause of recurrent LVAD pump thrombosis. ( 25545600 )
2015
6
Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment. ( 25479916 )
2015
7
Superior Mesenteric Artery Syndrome Associated with Rapid Weight Loss Attributed to Amphetamine Abuse. ( 26351593 )
2015
8
Extreme Procalcitonin Elevation without Proven Bacterial Infection Related to Amphetamine Abuse. ( 24826347 )
2014
9
Factors associated with buprenorphine compared to amphetamine abuse among clients seeking treatment in Finland. ( 24560129 )
2014
10
Efficacy of psychostimulant drugs for amphetamine abuse or dependence. ( 23996457 )
2013
11
Androgenic anabolic steroid, cocaine and amphetamine abuse and adverse cardiovascular effects. ( 24719633 )
2013
12
Amphetamine abuse in Sweden: subject demographics, changes in blood concentrations over time, and the types of coingested substances. ( 23422398 )
2013
13
Amphetamine abuse in emergency department patients undergoing psychiatric evaluation. ( 22538120 )
2012
14
Acute demyelination in a person with amphetamine abuse. ( 22937385 )
2011
15
Rhabdomyolysis accompanied by spontaneous spinal subdural and subarachnoid hematoma related to amphetamine abuse. ( 20081506 )
2010
16
Modafinil treatment of amphetamine abuse in adult ADHD. ( 18562425 )
2009
17
The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007. ( 18368603 )
2008
18
Hospitalizations with amphetamine abuse among pregnant women. ( 18238971 )
2008
19
Amphetamine abuse in pregnancy: the impact on obstetric outcome. ( 17285340 )
2007
20
Contrast enhanced computer tomography of two cases of bilateral acute cortical necrosis, one of which related to amphetamine abuse. ( 16133628 )
2005
21
Coronary artery rupture associated with amphetamine abuse. ( 15316310 )
2004
22
Amphetamine abuse in pregnancy: anesthetic implications. ( 12872434 )
2003
23
Asia grapples with spreading amphetamine abuse. ( 12788585 )
2003
24
Rapidly growing internal carotid artery aneurysm after amphetamine abuse: case report. ( 12604995 )
2003
25
Altered response to intravenous thiopental and succinylcholine in acute amphetamine abuse. ( 12027859 )
2002
26
Massive intracerebral hematoma and extradural hematoma in amphetamine abuse. ( 11781916 )
2002
27
Vertebral artery dissection with amphetamine abuse. ( 17903796 )
2001
28
Amphetamine abuse during pregnancy: environmental factors and outcome after 14-15 years. ( 10954143 )
2000
29
Differentiation of clobenzorex use from amphetamine abuse using the metabolite 4-hydroxyclobenzorex. ( 11043667 )
2000
30
Amphetamine abuse and intracranial haemorrhage. ( 11089483 )
2000
31
Dexamphetamine substitution in the treatment of amphetamine abuse: an initial investigation. ( 10723851 )
2000
32
Intracerebral haemorrhage in a young adult: consider amphetamine abuse. ( 8731653 )
1996
33
Intracerebral haemorrhage due to amphetamine abuse: report of two cases with underlying arteriovenous malformations. ( 7786436 )
1995
34
Consumption coagulopathy after amphetamine abuse in pregnancy. ( 7660777 )
1995
35
Acute myocardial infarction resulting from amphetamine abuse: a spasm-thrombus interplay? ( 7985607 )
1994
36
Holoprosencephaly and trisomy 13 in a fetus with maternal early gestational amphetamine abuse--a case report. ( 8207770 )
1993
37
Intraventricular hemorrhage following amphetamine abuse. ( 2381547 )
1990
38
Acute myocardial infarction caused by intravenous amphetamine abuse. ( 2390398 )
1990
39
Bladder outflow obstruction secondary to intravenous amphetamine abuse. ( 2804574 )
1989
40
Intracranial haemorrhage caused by amphetamine abuse. ( 2614776 )
1989
41
Update on amphetamine abuse. ( 18750614 )
1989
42
Intracerebral hemorrhage and angiographic beading following amphetamine abuse. ( 3356528 )
1988
43
Psychotic manifestations in amphetamine abuse--experimental study on the mechanism of psychotic recurrence. ( 3797582 )
1986
44
Intravenous amphetamine abuse, primary cerebral mucormycosis, and acquired immunodeficiency. ( 3998699 )
1985
45
Nails as useful materials for detection of methamphetamine or amphetamine abuse. ( 6698458 )
1984
46
Amphetamine abuse and transsexualism. ( 7108506 )
1982
47
Acute cardiomyopathy secondary to intravenous amphetamine abuse. ( 7125413 )
1982
48
Violence: the ugly face of amphetamine abuse. ( 6114085 )
1981
49
Intracranial hemorrhage with amphetamine abuse. ( 7196521 )
1981
50
Intracranial hemorrhage with amphetamine abuse. ( 7191505 )
1980

Variations for Amphetamine Abuse

Expression for Amphetamine Abuse

Search GEO for disease gene expression data for Amphetamine Abuse.

Pathways for Amphetamine Abuse

GO Terms for Amphetamine Abuse

Cellular components related to Amphetamine Abuse according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 8.92 GRM2 GRM5 SLC6A2 SLC6A3

Biological processes related to Amphetamine Abuse according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.91 GRM2 GRM5 HTR1B HTR7 ITK MAPK14
2 response to drug GO:0042493 9.81 HTR1B MAOB SLC6A2 SLC6A3
3 response to ethanol GO:0045471 9.7 HTR1B MAOB SLC6A3
4 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.55 HTR1B MAP3K5
5 positive regulation of myoblast differentiation GO:0045663 9.54 MAP3K5 MAPK14
6 vasoconstriction GO:0042310 9.49 HTR1B HTR7
7 G-protein coupled glutamate receptor signaling pathway GO:0007216 9.48 GRM2 GRM5
8 adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway GO:0007196 9.46 GRM2 GRM5
9 monoamine transport GO:0015844 9.43 SLC6A2 SLC6A3
10 dopamine catabolic process GO:0042420 9.4 MAOB SLC6A3
11 dopamine uptake involved in synaptic transmission GO:0051583 9.37 SLC6A2 SLC6A3
12 p38MAPK cascade GO:0038066 9.32 MAP3K5 MAPK14
13 negative regulation of serotonin secretion GO:0014063 9.16 HTR1B MAOB
14 chemical synaptic transmission GO:0007268 9.02 GRM2 GRM5 HTR1B HTR7 SLC6A2
15 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 8.96 HTR1B HTR7

Molecular functions related to Amphetamine Abuse according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 glutamate receptor activity GO:0008066 9.26 GRM2 GRM5
2 serotonin binding GO:0051378 9.16 HTR1B HTR7
3 monoamine transmembrane transporter activity GO:0008504 8.96 SLC6A2 SLC6A3
4 dopamine:sodium symporter activity GO:0005330 8.62 SLC6A2 SLC6A3

Sources for Amphetamine Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....